Carcinoma Of Uteri Research Articles

Dosimetric Comparison of Isodose Surface Volume and Total Reference Air Kerma (TRAK) based Volume in Cervical Cancer Brachytherapy.

We aim to compare TRAK & TPS based isodose volumes in cervical cancer brachytherapy and assess the feasibility, accuracy and potential future implications of TRAK in this regard and as a newer emerging tool to assess treatment intensity in cervical cancer brachytherapy. one hundred patients with histologically proven squamous cell carcinoma of cervix uteri were assessed for brachytherapy (after completion of external radiation) and prospectively enrolled for the study. 60 Gy, 75 Gy, and 85 Gy isodose volumes were obtained from the TPS (VTPS) for 50, 25 & 25 patients with Manchester, Fletcher & interstitial implant respectively, receiving various fractionation schedules by Ir192 HDR remote after-loading system. Using the formula Vpred=4965(TRAK/dref)3/2+170(TRAK/dref)-1.5 the TRAK based isodose surface volumes (Vpred) were derived. Reference doses (dref) were calculated based on accumulated EBRT and brachytherapy doses. The two sets of volume were compared with respect to applicator type, standard, and optimised plan. Surrogate point A dose was also correlated. VTPS - Vpred were 5.24 ± 2.7%, all volumes being predicted within 10%. Correlation of TRAK vs VTPS60/ VTPS75/ VTPS85 showed R2 of 0.994, 0.987 and 0.971 respectively. There was no significant difference in predicted volumes with respect to applicator type. The surrogate point A showed mean volume and standard deviation of 7.44 ± 13.4%, 17.63 ± 16.38 and 3.5 ± 0.95 for Manchester optimised, Fletcher optimised and standard plans respectively. TRAK with point A (R2=0.5632), bladder (R2=0.2015) and rectal doses (R2=0.121) yielded no correlation. Volumes calculated by TRAK correlate with TPS obtained volumes significantly and the formula predicting isodose surface volumes within 10% accuracy for ICBT applications and not for pure interstitial implants. However, TRAK fails to correlate with surrogate point A, bladder and rectal doses hence has questionable utility as a marker for biological response & treatment intensity.

Synthesis of an Aryl-Semicarbazone-Based Cu(II) Complex for DNA and BSA Interaction and Anti-Cancer Activity against Human Cervix Uteri Carcinoma

The current study provides an in-depth analysis of the biological properties of a Cu(II) complex (C22H24Cu2N6O10) obtained from an aryl-semicarbazone ligand derived (L) from the condensation of 2,4-dihydroxy acetophenone and semicarbazide. The binding behavior of this complex with calf thymus DNA (CT-DNA) and bovine serum albumin (BSA) protein was explored using a combination of experimental and theoretical approaches. The results suggest that the complex binds with CT-DNA via a partial intercalation, and hydrophobic interaction. However, the complex binds to BSA protein predominantly through hydrogen bonding or van der Waals interactions rather than hydrophobic interactions. The molecular docking methodology was carried out to substantiate the experimental finding. Furthermore, the in vitro cytotoxicity study was conducted on human cervix uteri carcinoma (SiHa cancerous cell) lines upon exposure to the complex, and the findings reveal a considerable decrease in cell viability, when compared to the control. Overall, this study provides a comprehensive understanding of the biological potential of the Cu(II) complex and its potential as an anti-cancer agent.

Abstract LB061: Proteomic-based stemness score measure oncogenic dedifferentiation and enable the identification of druggable targets

Abstract Progression and therapeutic resistance in cancer have been strongly associated with the acquisition of a stemness phenotype. Here, we provide new stemness indices for assessing the degree of oncogenic dedifferentiation in tumor samples. We used a machine learning model to predict the stemness molecular phenotype based on proteomic data. The prediction model was built from human pluripotent stem cell from the Human Induced Pluripotent Stem Cells Consortium (HipSci) and applied to compute stemness indices on the Clinical Proteomic Tumor Analysis Consortium (CPTAC) tumor samples, consisting in their proteogenomic hallmarks of stemness. The obtained stemness scores based on protein expression are novel and original, and are significantly more robust compared to our previous published work. The obtained proteomic score is able to classify stem cells and non-stem cell classes. The initial analysis of over 2000 tumor samples obtained from twelve types of primary carcinomas of breast, ovary, lung, kidney, uterus, brain (pediatric and adult), head and neck, liver, stomach, colon, and pancreas has confirmed our previously published results. Indexing of CPTAC tumors with proteomic stemness score brought us with previously unappreciated findings. We integrated the stemness scores computed using proteins with gene expression, DNA methylation, microRNA, copy number alteration and protein post-translational modification to identify coherent proteogenomic stemness association. Our initial findings identified proteins and phospho-proteins as active nodes of signaling pathways and transcriptional networks that drive aggressiveness of the primary tumors that cause resistance to existing therapies. The correlation between stemness scores and protein expression resulted in the identification of potential drug targets for anti-cancer therapy both tumor-specific and shared among different tumor types. Our results also revealed stemness-associated proteins predictive of clinical outcome across analyzed tumor types. Finally, we validated some stemness targets by immunohistochemistry in independent samples and confirmed the association with clinical outcome. Targeting the proteins here identified and cellular mechanisms that drive a stemness phenotype with existing or novel drugs may eventually lead for clinical development of effective cures for cancer patients. Citation Format: Tathiane M. Malta, Iga Kołodziejczak, Renan Simões, Antonio Colaprico, Erik Storrs, Francesca Petralia, Felipe da v Leprevost, Rossana L. Segura, Elizabeth Demicco, Alexander J. Lazar, Weiping Ma, Pietro Pugliese, Michele Ceccarelli, Bozena Kamińska, Alexey I. Nesvizhski, Bing Zhang, Henry Rodriguez, Mehdi Mesri, Ana I. Robles, Clinical Proteomic Tumor Analysis Consortium, Li Ding, Maciej Wiznerowicz. Proteomic-based stemness score measure oncogenic dedifferentiation and enable the identification of druggable targets [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB061.

Biophysical insights into the binding capability of Cu(II) schiff base complex with BSA protein and cytotoxicity studies against SiHa

Herein, we have explored the effects of chlorinated mononuclear Cu(II) complex upon binding with BSA protein (bovine serum albumin) and its in vitro anti-proliferative potentiality against SiHa cell. The complex was synthesized involving a Schiff base ligand having N,N,O donor centers and characterized by several spectroscopic studies. Structure, DFT studies and Hirshfeld surface (HS) analyses were identified using crystallographic computational studies. The binding interaction with BSA depicts the efficacy of the complex towards promising binding of it with BSA. Further, the complex shows a moderate cytotoxicity against SiHa cancer cell signifying its potentiality as an anti-proliferative agent for human cervix uteri carcinoma.

Glyco-Polypeptides (Comosain) in Treating of Various Types of Late-Stage Refractory Solid Carcinoma in Humans - A DoubleBlind Study-Case Report of 126 Patients

Glyco-polypeptides (Comosain, Bromelain) induced leucocyte binding ability to tumor surface antigens, such as interleukin 2, 6, 8, and TNFs, is known as an immuno-target therapy. Using different concentration of Bromelain proteinases in 6 types of cancer cell, it resulted in hydrolysis, fibrinolysis, necrosis, and anti-metastatic effects in tumor cells. Anti-cancer effects were achieved in carcinoma of lung, breast, colon, ovary, cervix, and uterus. Investigation of anti-metastatic effects in Bromelain were carried out in a double-blind study: low dose cohort was on 10 mg/kg/day and a high dose cohort which was on 50 mg/kg/day for a period of over six months. A total of 83 patients with 3rd and 4th stage of refractory solid tumors were enrolled, whom at least previously failed on two regimens of chemotherapy and/or failed on radiation therapy. The rates of Complete Response (CR) and Partial Responses (PR) in high dose cohort are astonishing with 52% and 27% respectively. The Progress Disease (PD) was 10%, and the Stable Disease (SD) was 11%. The implications and results of the findings are discussed with in view of the reported anti-metastatic activity of orally administrated Bromelain.

Medicinal Importance of Flavonoid “Eupatorin” in the Health Sectors: Therapeutic Benefit and Pharmacological Activities Through Scientific Data Analysis

Background: Herbal medicines have been used in the health sector for the treatment of human disorders from the ancient time till the modern age. Plant based herbal products have an important place in medicine due to their health beneficial potential and pharmacological activities. Traditional medicines have been used in developing country, such as India to the developed countries such as the USA and Europe. Traditional medicines have been used in the health sectors for the treatment of numerous types of human disorders. Phytoconstituents play an important role in the growth, reproduction and development of the human being. Plant products have been used for the treatment of skin disorders, wounds, and various forms of inflammatory diseases. Flavonoids are a colorful component of fruits, seeds, vegetables, nuts and plants. Flavonoids have been used for the treatment of human disorders due to their vast pharmacological activities. Methods: Scientific information on eupatorin has been collected from different literature sources and analyzed in order to know the health benefit of eupatorin in medicine. All the scientific information presented here is collected from various databases such as Google, PubMed, and Science Direct etc. Pharmacological activity data of eupatorin have been collected from various literature databases and analyzed here to know the beneficial health potential of eupatorin in medicine. However, important analytical tools for the separation, isolation and identification of eupatorin have also been discussed in the present paper. Results: Eupatorin (39,5-dihydroxy-49,6,7-trimethoxyflavone) is a flavone class flavonoidal compound found to be present in the Orthosiphon stamineus, Salvia mirzayanii, Lantana montevidensis, Lantana montevidensis and Tanacetum vulgare. Eupatorin have been used against bronchitis, stomach disorders and various forms of cancer. Eupatorin have a potential role in various cancerous disorders, such as human uterus carcinoma, human gastric adenocarcinoma, breast carcinoma, melanoma and colon carcinoma. Pharmacological data analysis revealed the effectiveness of eupatorin in human cancer and various types of inflammatory disorders. However, the effectiveness of eupatorin against microorganism and enzymes were also presented in the present work with their herbicidal and vasorelaxation potential in the medicine. Eupatorin has a valuable role in the development of adjuvant chemotherapeutic agents. Conclusion: Present review will be beneficial to the researcher to understand the physiological importance of eupatorin in medicine for the development of newer and effective medicine.

A Nomogram-Based Risk Classification System Predicting the Overall Survival of Patients With Newly Diagnosed Stage IVB Cervix Uteri Carcinoma.

Background: This study constructed and demonstrated a model to predict the overall survival (OS) of newly diagnosed distant metastatic cervical cancer (mCC) patients.Methods: The SEER (Surveillance, Epidemiology, and End Results) database was used to collect the eligible data, which from 2010 to 2016. Then these data were separated into training and validation cohorts (7:3) randomly. Cox regression analyses was used to identify parameters significantly correlated with OS. Harrell's Concordance index (C-index), calibration curves, and decision curve analysis (DCA) were further applied to verify the performance of this model.Results: A total of 2,091 eligible patients were enrolled and randomly split into training (n = 1,467) and validation (n = 624) cohorts. Multivariate analyses revealed that age, histology, T stage, tumor size, metastatic sites, local surgery, chemotherapy, and radiotherapy were independent prognostic parameters and were then used to build a nomogram for predicting 1 and 2-year OS. The C-index of training group and validation group was 0.714 and 0.707, respectively. The calibration curve demonstrated that the actual observation was in good agreement with the predicted results concluded by the nomogram model. Its clinical usefulness was further revealed by the DCAs. Based on the scores from the nomogram, a corresponding risk classification system was constructed. In the overall population, the median OS time was 23.0 months (95% confidence interval [CI], 20.5–25.5), 12.0 months (95% CI, 11.1–12.9), and 5.0 months (95% CI, 4.4–5.6), in the low-risk group, intermediate-risk group, and high-risk group, respectively.Conclusion: A novel nomogram and a risk classification system were established in this study, which purposed to predict the OS time with mCC patients. These tools could be applied to prognostic analysis and should be validated in future studies.

Abstract 3113: Pan-cancer stemness defined by CPTAC proteogenomics guides personalized therapies

Abstract Cancer progression involves the gradual loss of a differentiated phenotype and acquisition of progenitor and stem cell-like features. Here, we provide new stemness indices for assessing the degree of oncogenic dedifferentiation. We used machine learning approaches to extract epigenetic, transcriptomic, and proteomic features from human stem cells and applied the computed result to index the Clinical Proteomic Tumor Analysis Consortium (CPTAC) tumor samples by their proteogenomic hallmarks of stemness. Leveraging the resource generated by Human Induced Pluripotent Stem Cells Consortium (HipSci), we extracted stemness signatures from the coherent epigenetic, transcriptomic, and proteomic datasets, using one-class logistic regression machine learning algorithm. The newly obtained stemness scores based on the DNA methylation and gene expression are significantly more robust compared to our previous published work based on the dataset obtained from a smaller number of samples with only genomics data. The stemness score computed by machine learning algorithms using proteomic datasets is novel and original. The obtained proteomic score is able to classify stem cells and non-stem cell classes. Indexing of CPTAC tumors with proteomic stemness score brought us with previously unappreciated findings. We have used the stemness scores computed using gene expression, DNA methylation, and proteins and their modifications to interrogate the coherent proteogenomic CPTAC datasets. The initial analysis of over 2000 tumor samples obtained from twelve types of primary carcinomas of breast, ovary, lung, kidney, uterus, brain (pediatric and adult), head and neck, liver, stomach, colon, and pancreas has confirmed our previously published results. Importantly, our original proteomic-based score brought the analyses to a novel dimension, far beyond previously described results. The initial findings of our work identified proteins and phospho-proteins as active nodes of signaling pathways and transcriptional networks that drive aggressiveness of the primary tumors that cause resistance to existing therapies. Our results indicate that cancer stemness is associated with the engagement of developmental pathways shaping tumor plasticity. Progressive oncogenic de-differentiation of cancer cells impacts tumor microenvironment and is associated with “cold” tumors thus impairing anti-tumor immune response and limiting the efficacy of immunotherapies. Hallmarks of cancer stemness correlate with increased tumor pathology grade and clinical stage and results in worse survival of the cancer patients across analyzed tumor types. Targeting identified proteins and cellular mechanisms that drive lethal phenotype of de-differentiated tumors with existing or novel drugs may pave the way for clinical development of effective cures for cancer patients. Citation Format: Maciej Wiznerowicz, Antono Colaprico, Erik Storrs, Francesca Petralia, Iga Kołodziejczak, Felipe da Veiga Leprevost, Weiping Ma, Daniel Cui Zhou, Bo Wen, Alexander Lazar, Pietro Pugliese, Michele Ceccarelli, Bożena Kamińska, Jan Lubiński, Alexey Nesvizhskii, Bing Zhang, Henry Rodriguez, Ana L. Robles, Mehdi Mesri. Pan-cancer stemness defined by CPTAC proteogenomics guides personalized therapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 3113.

A case of synchronous serous ovarian cancer and uterine serous endometrial intraepithelial carcinoma

BackgroundSerous endometrial intraepithelial carcinoma (SEIC) is now considered to represent an early stage of uterine serous carcinoma (USC). It is an intraepithelial lesion but has been reported to cause extrauterine metastases. We report a case of SEIC with serous ovarian carcinoma and lymph node metastasis.Case presentationA 57-year-old post-menopausal woman (gravida 3, para 2, SA1) was referred to our hospital with lower abdominal pain. An ultrasound and MRI showed that the ovary had swollen to 8 cm in size and had a solid lesion. The uterus was normal. The patient underwent exploratory laparoscopy on the suspicion of torsion of the ovarian tumor. Intraoperative findings showed a right ovarian tumor, but no ovarian tumor torsion was observed. A small amount of bloody ascites was found in the Douglas fossa, and bleeding was observed from the tumor itself. A right salpingo-oophorectomy was then performed. Histopathological results revealed a high-grade serous carcinoma. Forty days after the first surgery, we performed a staging laparotomy: a total abdominal hysterectomy, left salpingo-oophorectomy, systematic pelvic and paraaortic lymphadenectomy, and a partial omentectomy. A complete cytoreduction was achieved. In the pathological examination, the invasion of the serous carcinoma was observed in the left ovarian ligament, and lymph node metastasis was found in the paraaortic lymph nodes. Atypical columnar cells formed irregular papillary lesions which had proliferated in the endometrium, and this was diagnosed as SEIC. The final diagnosis was serous ovarian cancer, FIGO stage IIIA1(ii), pT2bN1M0, with SEIC.ConclusionWe report a case of SEIC with synchronous serous carcinoma of the adnexa uteri. Both were serous carcinomas and, thus, it was difficult to identify the primary lesion. The distinction between metastatic cancer and two independent primary tumors is important for an accurate diagnosis and tumor staging. Histological diagnostic criteria remain controversial, and further development of a method for differentiating between both diseases is required.

Radical Radiotherapy of Locally Advanced Cervix Uteri Carcinoma

External beam radiotherapy with concomitant platinum-based chemotherapy followed by brachytherapy is defined as radical radiotherapy of cervix uteri carcinoma. Radical radiotherapy is the gold standard treatment for locally advanced cervix uteri carcinoma

Prognostic significance of poorly differentiated histology and impact of adjuvant chemotherapy in early squamous cell carcinoma of cervix uteri.

ObjectiveThis study is to determine whether the addition of cisplatin‐based chemotherapy after radical hysterectomy will improve the survival of low‐risk squamous cervical carcinoma with poor differentiation.MethodsPatients with low‐risk squamous cervical cancer (FIGO IA2–IIA, absent high‐ and intermediate‐risk factors after pathological evaluation) were eligible for this study. As first, the prognostic relevance of G3 versus G1/G2 among patients with low‐risk squamous cervical cancer was analyzed, then, the oncological results of postoperative chemotherapy among low‐risk squamous cervical cancer with poor differentiation was explored.ResultsTotally, there were 367 low‐risk squamous cervical cancer patients, of whom 161 were poor‐differentiated (47 in the chemotherapy group and 114 in the nonchemotherapy group), with a median follow‐up time of 56 months. Patients with G3 displayed a significantly worse overall survival (p = 0.035), and a higher recurrence rate (p = 0.014) than patients with G1/G2. Compared with the nonchemotherapy group, the hazard ratios (95%CI) for recurrence‐free survival in the chemotherapy group was 0.24 (0.06–0.93), (p = 0.038). No difference in overall survival was observed between the chemotherapy group and the nonchemotherapy group.ConclusionsThe addition of cisplatin‐based chemotherapy following surgery significantly improved recurrence‐free survival for low‐risk, poor differentiation, and early stage squamous cervical cancer patients.

Neurotrophic tyrosine receptor kinase (NTRK) 1 and 2 expression in squamous cell carcinoma and squamous intraepithelial lesions of the cervix uteri

Neurotrophic tyrosine receptor kinase (NTRK) 1 and 2 expression in squamous cell carcinoma and squamous intraepithelial lesions of the cervix uteri

Synchronous occurrence of two primary gynaecological tumors: A case report

Synchronous occurrence of two primary tumors is rare. Endometrial and ovarian cancers are the most frequently simultaneously occurring primary tumors. Here we are presenting, similar rare presentation of 40 years old lady who has been referred to us with complaint of abnormal uterine bleeding and lump abdomen since one year. Patient underwent total abdominal hysterectomy and bilateral salpingoopherectomy with surgical staging. Histopathological examination showed moderately differentiated endometroid ovarian carcinoma and endometroid adenocarcinoma of uterus with metastasis to cervix. Keywords: Synchronous, Primary tumors, Endometrial cancer, Ovarian cancer.

Trends in Cancer Incidence in US Adolescents and Young Adults, 1973-2015

Previous studies have demonstrated that adolescents and young adults (AYAs) with cancer are a distinct cancer population; however, research on long-term epidemiological trends and characteristics of cancers in AYAs is lacking. To characterize the epidemiology of cancer in AYAs aged 15 to 39 years with respect to (1) patient demographic characteristics, (2) frequencies of cancer types, and (3) cancer incidence trends over time. This retrospective, serial cross-sectional, population-based study used registry data from the Surveillance, Epidemiology, and End Results (SEER) database from January 1, 1973, to December 31, 2015 (SEER 9 and SEER 18). The study population was from geographically distinct US regions, chosen to represent the racial and ethnic heterogeneity of the country. Initial analyses were performed from January 1 to August 31, 2019. Incidence rates and descriptive epidemiological statistics for patients aged 15 to 39 years with invasive cancer. A total of 497 452 AYAs diagnosed from 1973 to 2015 were included in this study, with 293 848 (59.1%) female and 397 295 (79.9%) White participants. As AYAs aged, an increase in the relative incidence of carcinomas and decrease in the relative incidence of leukemias, lymphomas, germ cell and trophoblastic neoplasms, and neoplasms of the central nervous system occurred. Among the female AYAs, 72 564 (24.7%) were diagnosed with breast carcinoma; 48 865 (16.6%), thyroid carcinoma; and 33 828 (11.5%), cervix and uterus carcinoma. Among the male AYAs, 37 597 (18.5%) were diagnosed with testicular cancer; 20 850 (10.2%), melanoma; and 19 532 (9.6%), non-Hodgkin lymphoma. The rate of cancer in AYAs increased by 29.6% from 1973 to 2015, with a mean annual percentage change (APC) per 100 000 persons of 0.537 (95% CI, 0.426-0.648; P < .001). Kidney carcinoma increased at the greatest rate for both male (APC, 3.572; 95% CI, 3.049-4.097; P < .001) and female (APC, 3.632; 95% CI, 3.105-4.162; P < .001) AYAs. In this cross-sectional, US population-based study, cancer in AYAs was shown to have a unique epidemiological pattern and is a growing health concern, with many cancer subtypes having increased in incidence from 1973 to 2015. Continued research on AYA cancers is important to understanding and addressing the distinct health concerns of this population.

PET Radiomics Analysis for Prediction of Metabolic Complete Response of Primary Tumor After Chemo-Radiotherapy for Squamous Cell Carcinoma of Cervix Uteri

PET Radiomics Analysis for Prediction of Metabolic Complete Response of Primary Tumor After Chemo-Radiotherapy for Squamous Cell Carcinoma of Cervix Uteri

Trends and predictors of survival for small cell carcinoma of the cervix uteri: A SEER population study

ObjectiveSmall cell carcinoma of the cervix uteri (SCCC) is an uncommon cancer associated with unsatisfactory survival outcomes. We aimed to investigate the incidence and prognostic factors of survival in SCCC patients using the Surveillance, Epidemiology, and End Results database. MethodsEligible patients with histopathologic diagnoses of SCCC were identified between 2004 and 2015. Overall survival (OS) and cause-specific survival (CSS) for the included patients were calculated using the Kaplan-Meier method. Univariate and multivariate analyses of clinical factors were performed using Cox proportional hazard regression models. ResultsWe identified 272 SCCC patients based on predefined criteria. The average incidence of SCCC was 1.01 % per year between 2004 and 2015. The median OS and CSS were 17.0 and 19.0 months, respectively, accompanying with 5-year OS rate was 26.3 % and 5-year CSS rate was 30.1 %. In the multivariate analysis, advanced age (age ≥ 65 years old), late FIGO stage, surgery at the primary site, radiotherapy (RT) and chemotherapy (CT) were strong prognostic factors for OS. The corresponding variables for CSS were: advanced age, late FIGO stage, RT and CT. In the subgroup analysis for nonsurgical management of SCCC, the combination of RT and CT provided the best survival outcomes when compared with other therapeutic modalities. Again, advanced age was interrelated to worse survival outcomes for both OS and CSS. ConclusionsSCCC is an infrequent disease with aggressive nature, which lead to poor survival outcomes. In addition to other known parameters, advanced age is a strong predictive factor for OS and CSS. The combination of RT and CT was the best therapeutic strategy for patients who received nonsurgical management.

The Value of Magnetic Resonance in Assessment of Size, Invasion, Metastasis and Cervical Cancer Stage Classification

This study investigates the value of magnetic resonance (MR) in assessing size, invasion, lymph node metastasis and cervical cancer stage classification in 117 patients who underwent surgery for whole hysterectomy and pelvic lymph node dredge in Vietnam National Cancer Hospital from July 2016 to August 2018. The study results show that tumor size accuracy (Acc) was 93.2%; vaginal invasion Sp was 98.2%; Acc, 96.6%, NPV, 98.2%; parametrial invasion Sp, 98.2%; Acc, 98.3%, NPV, 100%; pelvic wall invasion Acc , 98.3%; Sp was 115/116, 99.1%; NPV, 99.1%; metastatic lymph node Sp, 98.0%; Acc, 88.9%; NPV, 89.8%. The Acc of the value of MR in cervical cancer stage diagnosis from stage IB was 96.1%; and the overall Acc was 82.9%. The study results also show that the use of MRI in combination with clinical examination in size, invasion, metastasis and cervical cancer stage classification is necessary to improve the accuracy of the diagnosis. &#x0D; Keywords&#x0D; Cervical cancer, MRI of cervix.&#x0D; References&#x0D; [1] Globocan Cervical Cancer, Estimated Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/old/FactSheets/ cancers/cervix - new.asp (accessed 30.06.2017). [2] Sala E, Wakely S, Senior E et al. MRI of malignant neoplasms of the uterine corpus and cervix. AJR Am J Roentgenol 188(6) (2007) 1577. [3] Hricak H, Lacey CG, Sandles LG et al. Invasive cervical carcinoma: comparison of MR imaging and surgical findings. Radiology 166(3) (1988) 623.[4] Ngo Thi Tinh, Research invasive level of cervical cancer on stage IB-IIA by clinical, magnetic resonance image and treatment results at K Hospital from 2007-2009. Doctor of Medicine thesis, Hanoi Medical University, 2011 (in Vietnamese).[5] Doan Van Ngoc. Research image characteristics and values of 1.5 tesla magnetic resonance in stage classification and follow treatment of cervical cancer. Doctor of Medicine thesis, Hanoi Medical University, 201 (in Vietnamese).[6] Susan JF, Ahmed MA, Masako YK et al. The Revised FIGO Staging System for Uterine Malignancies: Implications for MR Imaging. RadioGraphics 32(6) (2012). [7] Corrigendum to: Revised FIGO staging for carcinoma of the cervix uteri; Int J Gynecol Obstet 145 (2019) 129.[8] Hoang Duc Kiet. Magnetic resonance image of abdomen and pelvis. Medical Publishing House, (2016), pp.31-44, 329-334 (in Vietnamese).[9] Bourgioti C, Koutoulidis V, Chatoupis K et al. MRI findings before and after abdominal radical trachelectomy (ART) for cervical cancer: a prospective study and review of the literature. Clin Radiol. 69 (2014) 678.[10] Charis B, Konstantinos C, Lia AM, Current imaging strategies for the evaluation of uterine cervical cancer, World J Radiol, 28; 8(4) (2016) 342.&#x0D; &#x0D;

Is there any correlation between HPV and early radioresponse before brachytherapy in cervix uteri carcinoma?

The prognostic effect of human papilloma virus (HPV) on early radioresponse before brachytherapy was evaluated in locally advanced cervix uteri carcinoma patients. Between 2015 and 2018, 150 patients with locally advanced carcinoma of the cervix uteri from University of Health Sciences Okmeydani Training and Research Hospital and Istanbul Oncology Hospital underwent chemotherapy concomitant with external radiotherapy and brachytherapy after performing fluorodeoxyglucose positron emission tomography (FDG PET) and magnetic resonance imaging (MRI) for purposes of staging and treatment planning. The treatment results of patients analyzed retrospectively. The median age of 57 patients was 53years, and the initial tumor volume was 27cm3. The median follow-up period was 22months. The median tumor volume after external radiotherapy was significantly higher in patients without local control than those who responded to external radiotherapy (p = 0.031). The mean tumor diameter and volume in all HPV-negative patients after external radiotherapy were significantly higher than those of HPV-positive patients (p = 0.011 and p = 0.046, respectively). In a group of patients with poor early responses, local disease control could not be achieved despite the use of recommended higher doses of brachytherapy. We could not determine the correlation between HPV contamination and patients who had early response intervention. But residual tumor of more than 2cm in diameter after external radiotherapy may be a predictor of failed local control and development of metastasis within a short time.

Contributions of the newly revised 2018 international federation of gynecology and obstetrics staging of cervical cancer

Introduction. According to the latest data from International Agency for Research on Cancer from 2018, global burden of cancer cervical cancer is the fourth most common cancer in women worldwide. The aim of this article was to present the contributions of the new, revised 2018 International Federation of Gynecology and Obstetrics staging of carcinoma of the cervix uteri, allowing much more precise staging with the use of any imaging modalities and/or pathological findings to allocate the stage and provide more effective treatment. International Federation of Gynecology and Obstetrics staging system. The main changes in the new staging system were made in IB stage of the disease, which now includes 3 subgroups i.e. substages for every 2 cm increments in tumor size: stage IB1 (&lt; 2 cm), stage IB2 disease (2 to &lt; 4 cm), and stage IB3 (? 4 cm). This system also incorporates the lymph node status into stage III cervical cancer, allowing imaging and/or pathological findings of lymph nodes to the pelvic and/or para-aortic nodes to assign stage IIIC disease. Conclusion. The main goal of the new staging system revision was to improve the accuracy of staging in order to provide more refined understanding of prognostic groups and facilitate better treatment for women with invasive cervical cancer.

Epidemiologic fetaures and survival outcomes of carcinoma of the corpus uteri

Amaç: Ege Üniversitesi Hastanesinde 1992-2017 arası kanser tanı ve tedavisi yapılan 3379 korpus uteri kanserinin epidemiyolojik ve sağ kalım özelliklerini analiz etmek ve sonuçları literatürle karşılaştırmaktır.&#x0D; Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan korpus uteri kanseri verileri CANREG özel bilgisayar programına kayıt edilmiş, DSÖ ve SEER sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistik analizlerde Ki-kare, General Linear Model, Kaplan Meier sağ kalım analizleri uygulanmıştır. Kaplan Meier Sağ kalım analizinde Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistik analizlerde p